Failure of viridans group streptococci causing bacteremia in pediatric oncology patients to express superantigens

Journal of Pediatric Hematology/Oncology

Volumn 28, Issue 9, 2006, Pages 627-629

  Ohuoba, Esobe F ^a   Kansal, Rita G ^b   Hayden, Randall T ^a   Kotb, Malak ^b   Adderson, Elisabeth E ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Bacteremia; Oncology; Streptococcus; Toxic shock syndrome

Indexed keywords

SUPERANTIGEN;

ADOLESCENT; ADULT; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIGEN EXPRESSION; ARTICLE; BACTEREMIA; BACTERIUM CULTURE; BACTERIUM ISOLATE; CANCER PATIENT; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INFANT; LEUKEMIA; LYMPHOCYTE PROLIFERATION; MALE; MEDICAL RECORD; PRIORITY JOURNAL; SEPTIC SHOCK;

ADOLESCENT; BACTEREMIA; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; NEOPLASMS; STREPTOCOCCAL INFECTIONS; SUPERANTIGENS; VIRIDANS STREPTOCOCCI;

EID: 33749341807     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/01.mph.0000212986.41564.e9     Document Type: Article

References (10)

1. Llewelyn M, Cohen J. Superantigens: microbial agents that corrupt immunity. Lancet Inf Dis. 2002;2:156-162.
2. The Working Group on Serious Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome: rationale and consensus definition. JAMA. 1993;269:390-391.
3. Shenep JL. Viridans-group streptococcal infections in immunocompromised hosts. Int J Antimicrob Agents. 2000;14:129-135.
4. Lu H-Z, Weng X-H, Zhu B, et al. Major outbreak of toxic shock-like syndrome caused by Streptococcus mitis. J Clin Microbiol. 2003;41:3051-3055.
5. Alejandria MM, Lansang MA, Dans LF, et al. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev. 2002;CD001090.
6. Facklam R. What happened to the streptococci: overview of taxonomic and nomenclature changes. Clin Microbiol Rev. 2002;15:613-630.
7. Chatellier S, Ihendyane N, Kansal RG, et al. Genetic relatedness and superantigen expression in group A Streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases. Infect Immun. 2000;68:3523-3534.
8. Eriksson BK, Andersson J, Holm SE, et al. Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxinneutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome. J Inf Dis. 1999;180:410-418.
9. Norrby-Teglund A, Ihendyane N, Darenberg J. Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive Group A streptococcal infections. Scand J Infect Dis. 2003;35:683-689.
10. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Trans Med Rev. 2003;17:241-251.